The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended the licensing of an adapted (i.e. updated) bivalent vaccine that targets, in addition to the original SARS-CoV-2 strain, the BA.4 and BA.5 sub-variants of the Omicron variant. This recommendation will further expand the arsenal of vaccines available to protect people against COVID-19 as the pandemic continues and new waves of infections are expected in the autumn/winter period.
Comirnaty Original/Omicron BA.4-5 is intended for administration to persons aged 12 years and older who have received at least the initial COVID-19 vaccination regimen. This vaccine is an adapted version of the mRNA vaccine against COVID-19 disease, Comirnaty (Pfizer/BioNTech).
The vaccines are tailored to better address circulating variants of the SARS-CoV-2 virus and are expected to broaden protection against different variants. Timely evaluation of the available data on these adapted vaccines will allow their timely availability in the autumn vaccination campaigns.
The CHMP in its decision to recommend the licensing of Comirnaty Original/Omicron BA.4-5, considered all available data on Comirnaty and its adapted vaccines, including the recently licensed adapted Comirnaty Original/Omicron BA.1 as well as vaccines under investigation against other variants of concern.
The CHMP based its opinion in particular on the available clinical data with Comirnaty Original/Omicron BA.1. In addition to the fact that they contain mRNA matching different, but closely related, Omicron sub-variants, Comirnaty Original/Omicron BA.4-5 and Comirnaty Original/Omicron BA.1 have the same composition. Clinical studies with Comirnaty Original/Omicron BA.1 showed that the vaccine was more effective in inducing an immune response against the BA.1 sub variant than the original Comirnaty vaccine and was as effective as the original Comirnaty vaccine against the original strain. Adverse reactions were comparable to those observed with the original Comirnaty vaccine. This was further supported by data from investigational vaccines targeting other variants that have also shown similar safety profiles and predictable immune responses against the targeted strains.
The CHMP opinion on Comirnaty Original/Omicron BA.4-5 is also based on data on its quality and manufacturing process, which confirmed that it meets EU quality standards. In addition, immunogenicity data (the ability of the vaccine to trigger an immune response) from laboratory (non-clinical) studies provided supporting evidence that Comirnaty Original/Omicron BA.4-5 induces sufficient immunity against the targeted strains.
Based on all these data, the CHMP concluded that Comirnaty Original/Omicron BA.4-5 is expected to be more effective than the Comirnaty Original vaccine in inducing an immune response against BA.4 and BA.5 sub-variants. The safety profile of the vaccine is expected to be comparable to that of Comirnaty Original/Omicron BA.1 and the Comirnaty Original for which a large amount of data is available.
As clinical studies with Comirnaty Original/Omicron BA.4-5 are ongoing, the CHMP will take emerging clinical data as they are generated.
The CHMP opinion on Comirnaty Original/Omicron BA.4-5 will now be sent to the European Commission, which will adopt a final decision.
Use of COVID-19 vaccines
Together with the adapted Original/Omicron BA.1 which was recently licensed, this new adapted vaccine is expected to help maintain optimal protection against COVID-19 as the virus evolves.
The EU strategy is to have a wide range of adapted vaccines targeting different variants of the SARS-CoV-2 virus so that Member States have several options to meet their needs when planning their vaccination campaigns. This is a key element of the overall pandemic response strategy, as it is not possible to predict how the virus will evolve in the future and which variants will be released this winter.
Like all currently licensed COVID-19 vaccines, the Comirnaty prototype vaccine continues to be effective in preventing severe disease, hospitalisation and death associated with COVID-19 and will continue to be used as part of vaccination campaigns in the EU, particularly for initial vaccination schedules.
Last week, EMA and the European Centre for Disease Prevention and Control (ECDC) issued a joint statement providing updated public health recommendations on the use of newly licensed adapted COVID-19 vaccines to support Member States in their planning for autumn/winter vaccination campaigns. Although the tailored vaccines are licensed for use in persons aged 12 years and older who have received at least the initial COVID-19 vaccination regimen, the ECDC and EMA recommended that these booster doses should be targeted as a priority to persons at higher risk of severe disease due to risk factors.
National authorities in EU Member States will determine who should receive which vaccines and when, taking into account factors such as infection and hospitalisation rates, risk to vulnerable groups, vaccine coverage and vaccine availability.
How the Comirnaty Original/Omicron BA.4-5 vaccine works
Customized vaccines work in the same way as the original vaccines. They work by preparing the body to defend itself against COVID-19 disease.
Comirnaty Original/Omicron BA.4-5 contains molecules called mRNA that are instructed to create the spike proteins of the original SARS-CoV-2 virus strain and Omicron BA.4 and BA.5 sub-variants. The spike protein is a protein on the surface of the virus that the virus needs to enter body cells and may differ between virus variants. The spike proteins in BA.4 and BA.5 Omicron sub-variants are identical. By tailoring the vaccines, the goal is to broaden protection against different variants.
When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike proteins. Subsequently, the person's immune system will recognise these proteins as foreign and activate natural defences - antibodies and T cells - against them.
If, later, the vaccinated person comes into contact with the virus, the immune system will recognise the spike proteins on its surface and be ready to attack the virus. Antibodies and immune system cells can protect against COVID-19 disease by killing the virus through synergy, preventing it from entering the body's cells and destroying infected cells.
The mRNA molecules from the vaccines do not remain in the body but break down shortly after vaccination.
More about the process
The company responsible for marketing the Comirnaty vaccine submitted an application (also known as a variation application) to vary the existing marketing authorisation for the licensed Comirnaty vaccine to include the use of the adapted vaccine targeting the Omicron BA sub-variants.4 and BA.5 in addition to the original SARS-CoV-2 strain. The review was conducted by the EMA's Committee for Medicinal Products for Human Use (CHMP), which is responsible for questions on medicinal products for human use. The opinion of the CHMP has been forwarded to the European Commission, which will issue a final legally binding decision applicable to all EU Member States.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source